
|Articles|December 1, 2002
Novel proteomics test detects 95% of prostate cancers
Bethesda, MD-A screening technique based on the interplay of blood proteinsmay help clearly differentiate between prostate cancer and benign conditionslike BPH, according to a National Cancer Institute study. The test, whichis still under investigation, showed a specificity of 71% in men with marginallyelevated PSA levels, NCI researchers reported.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Experts urge FDA to revisit labeling for testosterone replacement therapy in men
2
Sildenafil cream for female sexual arousal disorder available to prescribe in select states
3
FDA approves first-line Zenflow system for the treatment of BPH
4
FDA approves gepotidacin for uncomplicated urogenital gonorrhea
5
















